Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Total Current Liabilities (2022 - 2025)

TriSalus Life Sciences' Total Current Liabilities history spans 4 years, with the latest figure at $11.5 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 12.43% year-over-year to $11.5 million; the TTM value through Dec 2025 reached $11.5 million, up 12.43%, while the annual FY2025 figure was $11.5 million, 12.43% up from the prior year.
  • Total Current Liabilities reached $11.5 million in Q4 2025 per TLSIW's latest filing, up from $10.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $32.4 million in Q4 2022 to a low of $1.7 million in Q2 2022.
  • Average Total Current Liabilities over 4 years is $10.2 million, with a median of $10.1 million recorded in 2024.
  • The largest YoY upside for Total Current Liabilities was 386.22% in 2023 against a maximum downside of 54.61% in 2023.
  • A 4-year view of Total Current Liabilities shows it stood at $32.4 million in 2022, then crashed by 54.61% to $14.7 million in 2023, then crashed by 30.36% to $10.2 million in 2024, then grew by 12.43% to $11.5 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Total Current Liabilities are $11.5 million (Q4 2025), $10.9 million (Q3 2025), and $9.3 million (Q2 2025).